We have established a comprehensive innovative drug research and development system, equipped with multiple platforms for drug molecule discovery and design. We have established a full spectrum of capabilities ranging from drug design, medicinal chemistry, to pharmacology and drug analysis laboratories. To date, we have successfully completed the screening of numerous new compounds across its pipeline, forming a rich product portfolio primarily focused on "First-in-class" and "Best-in-class" candidates that cover multiple hot therapeutic areas including oncology and autoimmune diseases. Among these, Mufemilast (for autoimmune diseases) and Hemay022 (for breast cancer) are among the candidates nearing the transition from clinical development to market launch, bringing hope to patients.
As of the end of 2024, We have filed over 70 invention patents, including 29 PCT applications, and has secured more than 100 domestic and international patent authorizations.
Cancer represents one of the major diseases threatening human health in recent years and is one of the primary research areas of Humay Pharmaceutical. Currently, the pipeline includes candidates such as Hemay022 and Hemay181, among which Hemay022 has advanced to Phase III clinical trials.
Autoimmune diseases arise from abnormal reactions in the human immune system, leading to attacks on the body's own normal tissues and cells, encompassing conditions such as rheumatoid arthritis, systemic lupus erythematosus, and psoriasis, etc. Currently, the under-development products include Mufemilast, Hemay007, Hemay808, etc., among which Mufemilast has obtained the 'Drug Registration Certificate'.
